PMID- 38108960
OWN - NLM
STAT- MEDLINE
DCOM- 20240227
LR  - 20240409
IS  - 1559-0259 (Electronic)
IS  - 1530-7905 (Linking)
VI  - 24
IP  - 2
DP  - 2024 Feb
TI  - The Role of mTOR in Doxorubicin-Altered Cardiac Metabolism: A Promising 
      Therapeutic Target of Natural Compounds.
PG  - 146-157
LID - 10.1007/s12012-023-09820-7 [doi]
AB  - Doxorubicin (DOX) is commonly used for the treatment of various types of cancer, 
      however can cause serious side effects, including cardiotoxicity. The mechanisms 
      involved in DOX-induced cardiac damage are complex and not yet fully understood. 
      One mechanism is the disruption of cardiac metabolism, which can impair cardiac 
      function. The mammalian target of rapamycin (mTOR) is a key regulator of cardiac 
      energy metabolism, and dysregulation of mTOR signaling has been implicated in 
      DOX-induced cardiac dysfunction. Natural compounds (NCs) have been shown to 
      improve cardiac function in vivo and in vitro models of DOX-induced 
      cardiotoxicity. This review article explores the protective effects of NCs 
      against DOX-induced cardiac injury, with a focus on their regulation of mTOR 
      signaling pathways. Generally, the modulation of mTOR signaling by NCs represents 
      a promising strategy for decreasing the cardiotoxic effects of DOX.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Yarmohammadi, Fatemeh
AU  - Yarmohammadi F
AUID- ORCID: 0000-0002-0552-8766
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Hesari, Mahvash
AU  - Hesari M
AUID- ORCID: 0000-0001-5884-0844
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Shackebaei, Dareuosh
AU  - Shackebaei D
AUID- ORCID: 0000-0002-5919-9750
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran. dshakebaei@kums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231218
PL  - United States
TA  - Cardiovasc Toxicol
JT  - Cardiovascular toxicology
JID - 101135818
RN  - W36ZG6FT64 (Sirolimus)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Humans
MH  - *Cardiotoxicity/metabolism
MH  - *Sirolimus
MH  - Autophagy
MH  - Doxorubicin/toxicity
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Oxidative Stress
MH  - Myocytes, Cardiac
MH  - Apoptosis
OTO - NOTNLM
OT  - Autophagy
OT  - Cardiotoxicity
OT  - Doxorubicin
OT  - mTORC1
OT  - mTORC2
EDAT- 2023/12/18 12:42
MHDA- 2024/02/27 06:44
CRDT- 2023/12/18 11:10
PHST- 2023/09/22 00:00 [received]
PHST- 2023/12/09 00:00 [accepted]
PHST- 2024/02/27 06:44 [medline]
PHST- 2023/12/18 12:42 [pubmed]
PHST- 2023/12/18 11:10 [entrez]
AID - 10.1007/s12012-023-09820-7 [pii]
AID - 10.1007/s12012-023-09820-7 [doi]
PST - ppublish
SO  - Cardiovasc Toxicol. 2024 Feb;24(2):146-157. doi: 10.1007/s12012-023-09820-7. Epub 
      2023 Dec 18.